Endurance (Cayman) Ltd Svf Sells 16,671 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) major shareholder Endurance (Cayman) Ltd Svf sold 16,671 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $6.07, for a total transaction of $101,192.97. Following the completion of the sale, the insider owned 15,353,338 shares of the company’s stock, valued at approximately $93,194,761.66. This trade represents a 0.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.10, for a total value of $78,348.40.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.08, for a total value of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.14, for a total value of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.05, for a total value of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.60, for a total transaction of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.69, for a total transaction of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total transaction of $2,503,901.52.

Vir Biotechnology Trading Down 0.3%

NASDAQ:VIR opened at $5.78 on Friday. The company has a market capitalization of $802.96 million, a P/E ratio of -1.45 and a beta of 1.27. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $14.45. The firm has a fifty day simple moving average of $5.16 and a 200-day simple moving average of $5.27.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The firm had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The business’s revenue was down 60.5% on a year-over-year basis. During the same quarter last year, the business earned ($1.02) EPS. Equities analysts forecast that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Hedge Funds Weigh In On Vir Biotechnology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VIR. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth about $35,000. GAMMA Investing LLC raised its holdings in shares of Vir Biotechnology by 524.3% during the first quarter. GAMMA Investing LLC now owns 7,111 shares of the company’s stock valued at $46,000 after acquiring an additional 5,972 shares during the last quarter. Apollon Wealth Management LLC acquired a new position in shares of Vir Biotechnology during the second quarter valued at approximately $50,000. Daiwa Securities Group Inc. lifted its position in shares of Vir Biotechnology by 2,200.6% in the second quarter. Daiwa Securities Group Inc. now owns 12,308 shares of the company’s stock valued at $62,000 after acquiring an additional 11,773 shares in the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Vir Biotechnology in the second quarter worth approximately $63,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on VIR shares. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Vir Biotechnology in a report on Monday, September 15th. Bank of America upgraded shares of Vir Biotechnology from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $12.00 to $14.00 in a research note on Wednesday, August 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Vir Biotechnology in a research report on Tuesday, October 14th. Evercore ISI initiated coverage on shares of Vir Biotechnology in a report on Wednesday, September 3rd. They issued an “outperform” rating and a $12.00 price target on the stock. Finally, Raymond James Financial assumed coverage on Vir Biotechnology in a research report on Friday, July 11th. They set an “outperform” rating on the stock. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.30.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).